MEDROL 4 MG TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

METHYLPREDNISOLONE

可用日期:

PFIZER CANADA ULC

ATC代码:

H02AB04

INN（国际名称）:

METHYLPREDNISOLONE

剂量:

4MG

药物剂型:

TABLET

组成:

METHYLPREDNISOLONE 4MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

ADRENALS

產品總結:

Active ingredient group (AIG) number: 0106290007; AHFS:

授权状态:

APPROVED

授权日期:

2003-09-19

产品特点

_MEDROL (methylprednisolone) – Product Monograph _
_Page 1 of 32_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MEDROL*
methylprednisolone
4mg & 16mg tablets, for oral use
USP
Glucocorticoid
Pfizer Canada ULC
17 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Initial Authorization:
May 30, 2001
Date of Revision:
MAR 12, 2024
Submission Control Number: 280540
* TM Pharmacia Enterprises S.A.
Pfizer Canada ULC, licensee
© Pfizer Canada ULC, 2023
_MEDROL (methylprednisolone) – Product Monograph _
_Page 2 of 32_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, General, Endocrine and
Metabolism
07/2023
8 ADVERSE REACTIONS
03/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1.
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
5
1.2
Geriatrics
................................................................................................................
5
2.
CONTRAINDICATIONS
.................................................................................................
5
4.
DOSAGE AND ADMINISTRATION
.................................................................................
6
4.1
Dosing Considerations
............................................................................................
6
4.2
Recommended Dose and Dosage Adjustment
....................................................... 6
4.5
Missed Dose
........................................